ThisCART19A

BIOLOGICAL10 trials

Sponsors

He Huang, Zhejiang University, Zhengzhou University, Fundamenta Therapeutics, Ltd., Henan Cancer Hospital

Conditions

AIDS Related Lymphoma and LympholeukemiaAllogeneic, CAR-T, Protein Sequestration, Non-gene EditedAllogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHLAutoimmune Hemolytic AnemiaB-ALLCD19 CAR-T Cell InfusionNon-Hodgkin's LymphomaPhiladelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Early Phase 1

Efficacy, Safety, and Pharmacokinetics of ThisCART19A Combined With Olverembatinib in Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.

Active, not recruitingNCT07074496

The First Affiliated Hospital of Soochow UniversityPhiladelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Start: 2024-01-01End: 2028-07-01Target: 20Updated: 2025-07-20

Phase 1

Evaluate the Safety and Effect of ThisCART19A in Patients With AIDS Related B Cell Lymphoma/Lympholeukemia

He HuangAIDS Related Lymphoma and Lympholeukemia

Start: 2022-03-18End: 2024-04-30Target: 18Updated: 2022-04-22

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B-NHL After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Zhejiang UniversityNon-Hodgkin's Lymphoma

Start: 2022-03-18End: 2024-04-30Target: 16Updated: 2022-04-27

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With MRD+ B-ALL

Zhejiang UniversityB-ALL

Start: 2022-03-18End: 2024-04-30Target: 16Updated: 2022-04-28

Evaluate the Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With R/R B-ALL

CompletedNCT05350787

Zhejiang UniversityB-ALL

Start: 2022-03-18End: 2025-05-21Updated: 2026-02-17

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Zhengzhou UniversityAllogeneic, CAR-T, Protein Sequestration, Non-gene Edited, r/r B-NHL

Start: 2022-09-02End: 2025-07-01Target: 15Updated: 2022-09-10

Safety and Efficacy of ThisCART19A Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B-cell Acute Lymphoblastic Leukemia

Fundamenta Therapeutics, Ltd.Allogeneic, CAR-T, Protein Sequestration, Non-gene Edited

Start: 2022-10-15End: 2025-07-22Target: 19Updated: 2022-10-12

Assessment of Safety and Efficacy of ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous Chimeric Antigen Receptor T- Cell(CAR-T) Therapy

Henan Cancer HospitalAllogeneic, CAR-T, Protein Sequestration, Non-gene Edited

Start: 2022-12-01End: 2025-08-01Target: 12Updated: 2022-12-07

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

Chongqing University Cancer HospitalRefractory or Relapsed B Cell Lymphoma

Start: 2023-05-31End: 2024-11-30Target: 12Updated: 2023-03-20

CAR-T for Autoimmune Hemolytic Anemia Patients Who Have Failed Three or More Lines of Therapy

RecruitingNCT06212154

Institute of Hematology & Blood Diseases Hospital, ChinaAutoimmune Hemolytic Anemia, CD19 CAR-T Cell Infusion

Start: 2024-01-20End: 2025-06-30Target: 13Updated: 2024-03-22

Related Papers

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

Blood2023-11-028 citations